Regeneron Pharmaceuticals (REGN) EPS 14.29 (exp. 10.21), Revenue 4.29bln (exp. 3.82bln)

A clean top- and bottom-line beat of this size is the kind of print that has historically produced a positive gap, with the durability of the move depending on what the call reveals about the drivers rather than the headline numbers themselves. For Regeneron the established pattern is that the market reads straight through the aggregate figures to the Eylea franchise: the split between the legacy formulation and the high-dose version, and the degree of erosion from competition, has tended to dominate the post-print narrative more than the beat itself. Dupixent, booked through the Sanofi collaboration, is the second swing factor, and commentary on its indication expansion has previously mattered as much as the quarter just reported. Pipeline updates, particularly around the oncology and obesity-adjacent programmes, are the usual source of secondary moves once the initial reaction settles. Worth noting is whether the beat is revenue-quality driven or flattered by cost timing and one-offs, a distinction that has separated sustained re-ratings from faded opens in past biotech prints of this kind. The call and any guidance revision are the follow-ons that set the tone into the session.